Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242379 (
lung cancer
)
71,905
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Positron emission tomography is a functional diagnostic imaging technique, which can accurately measure in vivo distribution of a radiopharmaceutical with high resolution. The ability of positron emission tomography to study various biologic processes opens up new possibilities for both research and day-to-day clinical use. Positron emission tomography has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality becoming part of armamentarium for the medical profession. The most widely used radiotracer in positron emission tomography is 18F-fluoro-2-deoxy-
D-glucose
(FDG), which is an analog of glucose. FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors, positron emission tomography has a high sensitivity and high negative predictive value. Positron emission tomography with FDG is now the standard of care in initial staging, monitoring the response to therapy and management of
lung cancer
, colorectal cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. The aim of this article is to review the clinical applications of positron emission tomography in oncology.
...
PMID:Positron emission tomography: clinical applications in oncology. Part 1. 1633 99
A 48-year-old male smoker presented with a chief complaint of persistent cough for three months. A CT scan revealed only a large right paratracheal mass. The plan was to obtain histological confirmation of suspected
lung cancer
via bronchoscopy and mediastinoscopy. A whole body 18F-FDG (2-deoxy-2-[18F]fluoro-
D-glucose
) PET Scan was ordered for staging and localization of the most accessible biopsy site. There was a large, intense hypermetabolic focus corresponding to the paratracheal lesion seen on CT, as well as a lesion in the right adrenal gland. There was also a superficial, subcutaneous hypermetabolic lesion in the mid-back. The subcutaneous lesion, which previously had not been noted, was biopsied and proved to be metastatic adenocarcinoma consistent with the lung primary. This case illustrates the clinical utility of reporting soft tissue abnormalities, which may provide an alternative, more readily accessible location for biopsy that is both safer and less expensive than bronchoscopy or mediastinoscopy.
...
PMID:Cutaneous metastatic lung cancer detected with 18F-FDG PET. 1661 24
Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-
D-glucose
(FDG), which is an analog of glucose. The FDG uptake in cells is directly proportional to glucose metabolism, which is increased many times in malignant cells. FDG-PET is now the standard of care in initial staging, monitoring the response to therapy and management of various cancers (e.g., breast cancer,
lung cancer
and lymphoma). However, the paucity of anatomical landmarks on PET images makes a consistent hardware fusion to anatomical cross-sectional data extremely useful. The introduction of combined PET-computer tomography (CT) scanners, which provide not only functional, but also structural information leading to a detection of subcentimeter lesions, made this technique useful in the early detection of the disease process and decreasing false-positive lesions. The aim of this article is to review the clinical applications (i.e., diagnosis, staging, evaluation of treatment response and restaging) using PET in patients with bone and soft-tissue sarcoma.
...
PMID:Role of PET/PET-CT in the management of sarcomas. 1692 90
Positron emission tomography (PET) using 2-(18)F-fluoro-2-deoxy-
D-glucose
(FDG), a radioactive derivative of glucose, is an advanced imaging tool, based on the increased glucose consumption of cancer cells. FDG-PET provides information that is not obtainable with other imaging modalities, and is very effective in the diagnosis and management of patients with various types of cancers. However, there are some limitations, such as low FDG uptake in some cancers, substantial FDG uptake in inflammatory cells, and the lack of anatomical information and poor imaging quality of PET. A recently developed integrated PET/computed tomography (CT) system, which combines a PET camera and CT scanner in a single session, has overcome these drawbacks by providing both anatomical and functional imaging at the same position. PET and/or PET/CT using FDG is clinically useful in the detection of cancer, the differentiation of malignant and benign lesions, the staging of cancer before therapy, and the assessment of cancer therapy, as well as for determining the recurrence after therapy of most cancers, including
lung cancer
, gastrointestinal cancer, breast cancer, and malignant lymphoma. PET/CT has become the new standard approach to imaging in the diagnosis and management of many cancer patients.
...
PMID:PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. 1693 2
We report a rare case of symptomatic hypoglycemia in a patient with intra-abdominal recurrence of a previously resected gastrointestinal stromal tumor (GIST). The patient is a 65-year-old woman who underwent resection of a large abdominal mass arising from the stomach, histologically diagnosed as a high-grade leiomyosarcoma. She was lost to follow up. Five years later, the mass recurred; core biopsy demonstrated a CD 117-positive, spindle-cell tumor, consistent with a GIST. She was placed on Gleevec, as there was evidence of multifocal disease, but imaging revealed only mild improvement. Subsequently, her clinical status deteriorated, and she was hospitalized for dehydration, vomiting, and mental status changes. Her blood glucose on admission was 22 mg/dL, and a
dextrose
infusion (50%) was necessary to maintain adequate blood glucose levels. Measurements of insulin, proinsulin, c-peptide, beta-hydroxybutyrate, and thyroid-stimulating hormone were normal, as were cosyntropin stimulation and glucagon response tests. Suspicions arose for tumor-secreted insulin-like factor. She underwent resection of the dominant 44-cm recurrence, with immediate rebound hyperglycemia, followed by complete normalization of her blood glucose levels. She was discharged on postoperative Day 5 without symptoms or insulin, and is alive with disease at 20 months. Paraneoplastic syndromes occur in only 15 per cent of patients with known malignancies (e.g.,
lung cancer
and metastatic carcinoid), and are rarely reported in the setting of GIST. Hypoglycemia is most often observed in presence of insulinoma and only isolated case reports in GIST patients exist. Overexpression of insulin-like growth factor II is thought to be the mechanism of action. Supportive management and palliative resection or debulking is recommended when possible.
...
PMID:Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. 1721 25
Whole-body positron emission tomography (PET) with radiolabeled [18F]-fluoro-2-deoxy-
D-glucose
(18FDG) plays an important role in the diagnosis, staging, and management of
lung cancer
. The preferential accumulation of FDG in malignant cells assists in the differentiation of benign and malignant tissue. However, PET alone does not allow an accurate anatomic localisation of FDG uptake. The combination of PET with CT images improves the spatial resolution, sensitivity and specificity of the test. PET/CT, as with PET alone, is indicated for the diagnosis of pulmonary nodules as well as the locoregional and extrathoracic staging of non-small-cell
lung cancer
(NSCLC). In many published studies, PET/CT has been shown to be superior to CT alone, to PET alone, or to both imaging techniques used separately to evaluate pulmonary nodules or for staging NSCLC. Now, PET/CT imaging is being investigated in the staging and management of small-cell
lung cancer
, in radiation treatment planning, in response prediction following treatment and in the detection of
lung cancer
recurrence in NSCLC. PET/CT is likely to have an important role in the management of
lung cancer
. New machines are in development and new radiopharmaceutical agents must be assessed.
...
PMID:[Diagnosis of lung cancer. Role of PET/CT fusion scan in lung cancer]. 1726 30
In the past 10 years, positron emission tomography (PET), usually with F-fluoro-2-deoxy-
D-glucose
(FDG), has become an important imaging modality in patients with
lung cancer
. FDG-PET is recommended for the diagnosis of indeterminate pulmonary nodules, for which it is significantly more accurate than computed tomography (CT) in the distinction between benign and malignant lesions. A large body of evidence convincingly demonstrates that loco-regional lymph node staging by FDG-PET (in correlation with CT images) is significantly superior to CT alone, with a negative predictive value equal or even superior to mediastinoscopy. FDG-PET also improves extrathoracic staging through detection of lesions missed at conventional imaging or characterization of lesions that remain equivocal on conventional imaging. Ongoing studies now concentrate on more advanced clinical applications, such as the planning of radiotherapy, the response evaluation after the induction of therapy, the early detection of recurrence, and the use in
lung cancer
screening. Technical innovations, such as PET cameras with better spatial resolution, or new radiopharmaceutical probes to study applications of PET in molecular biology hold promise for future refinements in this field.
...
PMID:PET scan in lung cancer: current recommendations and innovation. 1740 30
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer morbidity and mortality. Adjuvant chemotherapy improves survival in resected early-stage NSCLC. However, a significant proportion of patients with early-stage
lung cancer
are cured by surgery alone. There are no reliable clinical or molecular markers to predict outcomes after surgery in early-stage NSCLC. Positron emission tomography with 2-[F]fluoro-2-deoxy-
D-glucose
(FDG-PET) improves the accuracy of staging work-up in NSCLC. The standardized uptake value, a commonly used semiquantitative measure of FDG uptake, correlates with tumor doubling time and indices of cell cycling. Therefore, FDG-PET may be a useful predictor of outcome independent of its role in tumor staging. In this review, we critically examine the published studies on the utility of FDG-PET as a prognostic tool in patients with NSCLC and provide direction for future research.
...
PMID:Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. 1740 45
The characteristics of cases diagnosed as aspergillosis and Aspergillus spp. strains isolated from the respiratory tract samples in Mycology Laboratory of Trakya University Hospital between January 2002 and May 2006 were investigated. In this period, 137 bronchoalveolar lavages, 95 sputum, nine tracheal aspirates, three lung biopsies and one bronchial biopsy of 85 patients were processed. The samples were incubated in 25 degrees C and 35 degrees C media by culturing on brain heart infusion agar with blood and Sabouraud
dextrose
agar. Presence of leucocytes and fungal structures were searched in the smear stained by Gram and Giemsa. The patient was defined as probable aspergillosis case, if he/she patient had clinical findings, lung infiltration or fungus ball radiologically, at least one risk factor predisposing to aspergillosis and isolation of Aspergillus spp. in lower respiratory tract samples without finding of other nonmycotic infection. Of 22 patients isolated Aspergillus spp., 13, six, two, one were internalized in chest diseases, haemotology, neurosurgery and oncology clinics, respectively. Seven positive cultures were considered as findings of aspergillosis. Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger were isolated in three, two, and two patients, respectively. Fungal structures were detected in only one sample in the direct microscopical examination. Ages of seven patients, five were males and two were females, were between 15 and 60. Predisposing risk factors were acute leukemia in six patients and
lung cancer
in one patient. Five patients were neutropenic and one was neutrophylic. Fungus ball was detected in radiological imaging of one patient, had a pulmonary cavitary lesion. Conventional amphotericine B was used in their therapies. Antifungal agents were switched to caspofungin and itraconazole in two and one patients, respectively. Three patients died in four weeks after isolation of Aspergillus spp. Aspergillosis cases were not high in our hospital because of absence of transplantation center for bone marrow or solid organ.
...
PMID:[Aspergillus spp. isolations from respiratory tract samples in Trakya University Hospital]. 1760 44
Positron emission tomography (PET) using 18F-2-deoxy-
D-glucose
, a
D-glucose
analog labeled with fluorine-18, complements conventional radiologic assessment in the evaluation of patients with nonsmall-cell
lung cancer
(NSCLC). PET is being routinely used to improve the detection of nodal and extrathoracic metastases. PET is also currently being evaluated in the assessment of prognosis and therapeutic response and by potentially allowing an earlier assessment of response may prove invaluable in the oncologic management of patients. The article discusses the diagnosis, staging, and assessment of treatment response and prognosis with an emphasis on the appropriate clinical use of PET in management.
...
PMID:Positron emission tomography imaging in nonsmall-cell lung cancer. 1789 84
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>